Is Cocrystal Pharma Inc (COCP) overvalued? · rev $105.0K
Cocrystal Pharma Inc (COCP) is a biotechnology company listed on US.
This page asks whether Cocrystal Pharma Inc (COCP) looks expensive on cached numbers — not a short thesis.
Latest reported COCP revenue for 2026-06-30 was $105.0K. Net income was -$3.2M. Revenue was down 53.3% from 2026-03-31 to 2026-06-30. COCP currently screens at market cap $13.3M.
COCP currently screens at market cap $13.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next COCP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the COCP stock page for the full model, not this heading.
Not investment advice.